Healthcare / BiotechnologySwiss
$0.05
-0.00 (-0.44%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-5.4M · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-141.2%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-72.4%
FCF CAGR
—
FCF margin
-7243.8%
FCF / Net income
0.32x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $29972.0 · net income $-6.7M · FCF $-2.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $29972.00 | $29972.00 | $404102.00 | $1.6M | $1.4M |
| Net Income | $-6.7M | $-6.7M | $7.1M | $-10.6M | $-20.8M |
| EBITDA | $-6.8M | $-6.8M | $-4.6M | $-2.2M | $-10.5M |
| EPS | — | — | 0.07 | -0.14 | -0.46 |
| Operating Margin | -9390.8% | -9390.8% | -681.8% | -139.1% | -741.0% |
| Net Margin | -22448.4% | -22448.4% | 1746.0% | -654.5% | -1462.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.30 | 0.08 |
| Current Ratio | 1.40 | 1.40 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.2M | $-2.2M | $-5.4M | $-8.0M | $-16.4M |
| Returns | |||||
| ROE | -141.2% | -141.2% | 72.9% | -921.6% | -423.5% |
| Valuation | |||||
| P/E | — | — | 0.94 | — | — |
| P/B | 1.12 | 1.12 | 0.67 | 3.23 | 2.24 |
| Growth & Yield | |||||
| Revenue Growth | -92.6% | -92.6% | -74.9% | 13.4% | — |
| EPS Growth | — | — | 150.0% | 69.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.1%
Start / end P/E
n/dx → n/dx
EPS bridge
0.07 → n/d
Residual
-23.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.